Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MPN Advances Day 2017 | MPNs and thrombosis: reducing the risk

Patients with myeloproliferative neoplasm (MPNs) are at a higher risk of mortality due to thrombosis compared with unaffected individuals. Speaking from the Myeloproliferative Neoplasms Advances Day 2017 in London, UK, Tiziano Barbui, MD, from Hospital Papa Giovanni XXIII, Bergamo, Italy, discusses this issue and highlights the efforts being made to combat it, including cytoreductive therapy and anticoagulants. Prof. Barbui then provides an overview of his group’s exciting ongoing studies, which are collecting data from over 1,000 MPN patients.